Key result
Ropinirole protects motor neurons in ALS by suppressing toxic de novo cholesterol synthesis.
Why the study?
Cholesterol dysmetabolism in motor neurons has emerged as a central pathogenic axis and candidate therapeutic target in amyotrophic lateral sclerosis, while the effects of statins appear heterogeneous and context-dependent.
Do interventions targeting cholesterol dysmetabolism (such as statins or ropinirole hydrochloride) reduce ALS onset risk or improve survival and motor neuron function in ALS patients and preclinical models?
Do interventions targeting cholesterol dysmetabolism (such as statins or ropinirole hydrochloride) reduce ALS onset risk or improve survival and motor neuron function in ALS patients and preclinical models?
Answers are grounded in this paper and cite their sources.
This review highlights neuronal cholesterol dysmetabolism and oxysterol toxicity as central drivers of ALS pathogenesis, positioning cholesterol biosynthesis suppression (such as with ropinirole) and genetic risk stratification as promising translational strategies while clarifying that epidemiological evidence does not support routine statin discontinuation in patients with cardiovascular indications.
In amyotrophic lateral sclerosis (ALS), cholesterol dysmetabolism in motor neurons has emerged as a central pathogenic axis. Oxysterols generated under oxidative stress exert potent lower motor neuron toxicity via lysosomal and mitochondrial dysfunction and by triggering oxiapoptophagy, a form of cell death in which oxidative stress, apoptosis, and autophagy co-occur. Moreover, TAR DNA-binding protein 43 (TDP-43) dysfunction and pathogenic variants in ALS-related genes including C9orf72, VAPB, and SIGMAR1 can amplify lipid toxicity through impaired function of mitochondria-associated endoplasmic reticulum membranes (MAMs) and defective intracellular cholesterol trafficking. Genome-wide association studies (GWAS) and Mendelian randomization (MR) analyses indicate that genetically predicted elevations in low-density lipoprotein cholesterol (LDL-C), total cholesterol, and apolipoprotein B (ApoB) are associated with increased ALS risk, whereas the effects of statins appear heterogeneous and context-dependent, varying by agent, dose, and treatment duration. In drug discovery using patient-derived induced pluripotent stem cell (iPSC)-derived lower motor neurons (iPSC-LMNs), ropinirole hydrochloride suppresses the expression of enzymes involved in de novo cholesterol synthesis while reducing reactive oxygen species, inhibiting aggregation of TDP-43 and fused in sarcoma (FUS), and improving mitochondrial function; importantly, in vitro responsiveness correlates with clinical efficacy. Furthermore, integrating a polygenic risk score (PRS) for total cholesterol with iPSC-LMN phenotypes has been proposed as a stratification strategy to define an ALS subtype driven by hyperactive cholesterol metabolism and to identify patients more likely to benefit from cholesterol biosynthesis–suppressing therapies. Collectively, candidate disease-modifying interventions targeting cholesterol dysmetabolism are increasingly positioned as a promising translational research axis in ALS.
No takes yet. Share an insight, caveat, or question.
Morimoto et al. (2026) conducted a review in Amyotrophic lateral sclerosis (ALS). Cholesterol dysmetabolism and cholesterol-modulating therapies (statins, ropinirole hydrochloride) was evaluated on ALS pathogenesis, onset risk, and motor neuron survival. Cholesterol dysmetabolism and oxysterol toxicity drive motor neuron degeneration in ALS, while ropinirole suppresses de novo cholesterol synthesis to improve neuronal survival.
Synapse has enriched 10 related papers. Consider them for comparative context: